Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
76,991,404
-
Total 13F shares
-
20,253,624
-
Share change
-
+704,639
-
Total reported value
-
$121,519,006
-
Put/Call ratio
-
90%
-
Price per share
-
$6.00
-
Number of holders
-
64
-
Value change
-
+$4,442,643
-
Number of buys
-
41
-
Number of sells
-
13
Institutional Holders of Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) as of Q3 2021
As of 30 Sep 2021,
Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) was held by
64 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,253,624 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, Carmignac Gestion, ACT Capital, L.L.C., VANGUARD GROUP INC, ACUTA CAPITAL PARTNERS, LLC, TWO SIGMA ADVISERS, LP, TWO SIGMA INVESTMENTS, LP, MORGAN STANLEY, BlackRock Inc., and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
64
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.